InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology (ACC).
The meeting, named ACC.10 and i2 Summit, is being held from March 14 – 16, 2010 at the Georgia World Congress Center in Atlanta. In addition to several oral presentations featuring LipiScan, InfraReDx has organized a "Meet the Experts" series of discussions at the Company's booth (#254) in which leading cardiologists will highlight LipiScan's capabilities in identifying and characterizing lipid core (fatty) plaque.
InfraReDx's LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be "vulnerable plaque" that can rupture and form dangerous blood clots leading to coronary thrombosis. LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.
"One of the biggest challenges facing interventional cardiologists today is the ability to detect vulnerable coronary and fatty plaques," said Brijeshwar S. Maini, M.D., F.A.C.C, co-chair cardiovascular research, Pinnacle Health at Harrisburg Hospital. "As a result of improved imaging and diagnostic capabilities, however, physicians can now be armed with that information and are able to make important advances and improvements in patient care. This year's ACC meeting provides us with a great opportunity to interact with our colleagues, share key learnings and discuss important steps forward."
"We are pleased to be working so closely with these world renowned cardiology experts and leaders as they strive to improve patient care and we advance our LipiScan coronary imaging system," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "Through our close collaborations with these physicians and specialists, we are continuing to increase our working knowledge, enhance our LipiScan system and, ultimately, to significantly improve the imaging capabilities for interventional cardiologists and their patients. We are looking forward to a productive conference and many lively discussions at our booth about advancing the current standard of cardiac care."